According to a report from Reuters, Altria is asking the US Federal Trade Commission to drop its charges against the company's purchase of 35% of Juul in 2018. On March 3rd, the tobacco giant announced that it had exchanged its shares for Juul's heated tobacco intellectual property patents.
The Federal Trade Commission believes that Altria's $12.8 billion investment in Juul violates antitrust laws, as the company gained market position through an acquisition rather than continuing competition with Juul in the closed e-cigarette market.
In February 2022, an administrative judge dismissed charges by the Federal Trade Commission, stating that the evidence did not support the alleged violation. The next step is for the entire Commission to decide whether to accept the ruling and dismiss the case brought by the FTC.
However, Altria recently pulled out its investment in Juul and terminated a non-compete agreement with Juul that had previously been opposed by the Federal Trade Commission.
The transaction no longer has any parts that require accusation, as it has become meaningless," wrote Altria Group and Juul in documents submitted to the Federal Trade Commission.
Reference:
Altria has requested the Federal Trade Commission to dismiss the lawsuit regarding its acquisition of Juul.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
